OHSU Knight Cancer Institute

OHSU 奈特癌症研究所

• 批准号: 10411201
• 负责人: BRIAN J DRUKER
• 金额: $ 289.15万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411201
• 关键词: Achievement; Advanced Malignant Neoplasm; Advisory Committees; Area; Atlases; Automobile Driving; Behavior; Blood Tests; Breast; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivor; Catchment Area; Characteristics; Climate; Clinical; Clinical Cancer Center; Clinical Trials; Collaborations; Colonoscopy; Colorectal; Communities; Community Outreach; Comprehensive Cancer Center; County; Detection; Development; Doctor of Medicine; Drug resistance; Early Diagnosis; Employee; Enrollment; Ensure; Evaluation; Event; Exercise; Extramural Activities; Funding; Genetic Screening; Goals; Gold; Grant; Guidelines; Health Sciences; Hereditary Nonpolyposis Colorectal Neoplasms; Human; Human Papilloma Virus Vaccination; Immunotherapeutic agent; Individual; Infrastructure; Institutes; Institution; International; Intervention; Investments; Knowledge; Lead; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Mission; Molecular Target; NCI-Designated Cancer Center; National Cancer Institute; Oncology; Oregon; Pancreas; Patient-Focused Outcomes; Patients; Peer Review; Performance; Persons; Pilot Projects; Prevention; Prevention strategy; Process; Proteomics; Publications; Publishing; Reporting; Research; Research Personnel; Resource Sharing; Science; Screening for cancer; Solid Neoplasm; Strategic Planning; Systems Biology; Testing; The Cancer Genome Atlas; Tobacco Use Cessation; Training Programs; Training Support; Training and Education; Treatment Side Effects; Treatment-Related Cancer; Trust; Tumor Biology; Tumor-infiltrating immune cells; Universities; Work; anti-racism; anticancer research; base; cancer genetics; cancer genome; cancer prevention; clinical care; cohort; colon cancer screening; combat; community engagement; community organizations; community partnership; design and construction; diversity and inclusion; drug sensitivity; improved; improved outcome; innovation; investigator-initiated trial; leukemia; leukemia/lymphoma; lung cancer screening; malignant breast neoplasm; meetings; melanoma; member; molecular targeted therapies; next generation; pandemic disease; population based; precision medicine; precision oncology; professional atmosphere; programs; ranpirnase; recruit; screening guidelines; symposium; targeted cancer therapy; targeted treatment; translational oncology; translational progress; treatment trial; tumor; tumor-immune system interactions

PROJECT SUMMARY: Director’s Overview and Essential Characteristics Brian Druker, M.D., Center Director The Knight Cancer Institute (KCI) at Oregon Health & Science University (OHSU) in Portland, Oregon, is the only NCI-designated comprehensive cancer center in our catchment area, the state of Oregon. Our goal is to leverage our unique strengths into treatment, early detection, and prevention strategies to improve patient outcomes. The KCI has 191 members belonging to four scientific programs (Cancer Biology, Translational Oncology, Quantitative Oncology, and Cancer Prevention and Control) and using six Shared Resources. In the past reporting period, we developed and are implementing a comprehensive strategic plan which defines three focus areas for our center: Culture of Inclusion and Innovation, Precision Oncology, and Precision Early Detection. We have defined a comprehensive Diversity Action Plan to align with OHSU's efforts to be an anti- racist institution and drive our efforts to ensure a Culture of Inclusion and Innovation within the KCI. Using our strategic plan as a compass, we recruited 56 investigators, including 12 senior leaders. We completed the design and construction of three new buildings, which allowed for the consolidation of our research and clinical care. We restructured our administration and advisory committees to ensure our members' engagement in the effective implementation of the strategic plan. These efforts have led to substantial increases in CCSG metrics, including NCI funding, intra- and inter-programmatic interactions, collaborative grants, and investigator-initiated trials. Thus, our current 191 KCI members are supported by $61.6 million in extramural funding, $26.9 million from the NCI. In the current funding period, members published 2,265 cancer-focused, peer-reviewed publications, of which 26% were intra-programmatic, 20% inter-programmatic, and 63% externally collaborative. In 2019, the last full year before the pandemic, 556 patients were enrolled on interventional treatment trials, representing 11% of our 5,065 new analytic cases. We continue our leadership in precision oncology (implementing sophisticated clinical trials based on comprehensive tumor analytics) and in advancing understanding of tumor biology, the immune microenvironment, and immunotherapeutics. We have provided leadership in numerous collaborative NCI projects and were selected to lead a Biden Cancer Moonshot grant, Evaluation of Population Based Testing for HBOC and Lynch Syndromes. We have refined and improved screening guidelines for multiple cancers, contributed to exercise guidelines for cancer survivors, made substantial investments in Community Outreach and Engagement, and invested in the education and training of the next-generation cancer workforce. Together, these achievements have accelerated progress towards driving scientific discoveries in precision oncology and precision early detection through our culture of inclusion and innovation.

项目摘要：导演的概述和基本特征 Brian Druker，医学博士，中心主任 位于俄勒冈州波特兰的俄勒冈州健康与科学大学（OHSU）的骑士癌症研究所（KCI）是 只有NCI指定的综合癌症中心，俄勒冈州。我们的目标是 利用我们独特的优势进入治疗，早期发现和预防策略以改善患者 结果。 KCI有191名成员属于四个科学计划（癌症生物学，翻译 肿瘤学，定量肿瘤学以及癌症预防和控制），并使用六个共享资源。 在过去的报告期间，我们制定并正在实施一项全面的战略计划，以定义 我们中心的三个重点领域：包容和创新文化，精确肿瘤学和精确的早期 检测。我们已经定义了一项全面的多样性行动计划，以与OHSU的努力保持一致 种族主义机构，并推动我们为确保KCI内包容和创新文化的努力。使用我们的 作为指南针的战略计划，我们招募了56名调查人员，其中包括12位高级领导人。我们完成了设计 并建造了三座新建筑，这使我们的研究和临床护理综合了。 我们恢复了管理和咨询委员会，以确保我们的成员参与有效 实施战略计划。这些努力导致CCSG指标大幅增加，包括 NCI资金，内部和程序间相互作用，协作赠款和研究人员发起的试验。 这，我们目前的191个KCI成员得到了6160万美元的校外资金的支持，从 NCI。在当前的资金期间，成员出版了2,265个以癌症为中心的，同行评审的出版物 26％是截面性的，跨编程间的20％和63％的外部协作。 2019年 大流行前的最后一年，有556名患者参加了介入治疗试验，代表 我们的5,065例新分析案例中有11％。 我们继续领导精确肿瘤学（基于 全面的肿瘤分析）并在提高对肿瘤生物学的了解时，免疫 微环境和免疫治疗学。我们在众多合作NCI中提供了领导 项目并被选为领导Biden Cancer Moonshot Grant，评估基于人群的测试 HBOC和Lynch综合征。我们已经完善并改进了多种取消的筛选指南， 为癌症生存的锻炼指南做出了贡献，对社区宣传进行了大量投资 和参与，并投资于下一代癌症劳动力的教育和培训。一起， 这些成就加速了进步，以推动精确肿瘤学和 精确通过我们的包容和创新文化进行早期发现。